Clinical Trial: Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204457) titled 'Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old' on Sept. 25.

Brief Summary: Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Meningococcal Infections

Intervention: BIOLOGICAL: EG-MCV4

single intramuscular dose on Day 0

BIOLOGICAL: Menveo

single intramuscular dose on Day 0

Recruitment Status: NOT_YET_RECRUITING

Sponsor: EyeGene Inc.

Published by HT Digital C...